Steven Bulera, Corporate Vice President, Chief Scientific Officer: Safety Assessment, Charles River Laboratories, explores various use-cases of AI in improving drug discovery. It’s difficult, if not impossible, to escape the headlines and… Read More
DDW covers some of the biggest announcements from the second day of SLAS2026. Emulate showcases organ-chip platform at SLAS2026 Emulate has brought its AVA Emulation System to SLAS2026, showcasing the potential to accelerate drug development with a first-of-its-kind high-throughput organ-chip platform. Read more… Charles River and… Read More
Charles River Laboratories has announced a collaboration with software and assay developer Synthace to advance assay development in drug discovery. As part of the collaboration announced at SLAS2026, Charles River will give its clients access to Synthace’s approach to developing, automating and transferring more robust assays, which it says are faster and… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a research team found that a hidden molecular switch fuels obesity. Elsewhere, AI-generated… Read More
News round-up for 15 – 19 December by Bruno Quinney, Content Team at DDW. This week in DDW, a research team found that a hidden molecular switch fuels obesity. Elsewhere, AI-generated antibodies have been tolerated by human immune cells. The top stories: Scientists discover hidden molecular switch that… Read More
Charles River Laboratories has announced drug discovery companies will receive scientific and commercial expertise as part of the second cohort of its Cell and Gene Therapy Incubator Program (CIP). The CIP cohort includes six companies, four of which are advanced therapy developers (CureAge Therapeutics, InterAct Therapeutics, Jaan Biotherapeutics and Kopra Bio) and two enabling technology… Read More
Charles River Laboratories and Valo Health have announced the identification of an advanceable product candidate for the treatment of different forms of lupus and other autoimmune indications. The discovery was the first using Logica, an artificial intelligence (AI)-powered drug development solution that translates biological insights into optimised… Read More
Charles River Laboratories is hosting two drug discovery seminars in the UK in September. The first will be in Cambridge on 25 September covering drug discovery capabilities, with the second at the company’s Portishead, UK site covering immuno-oncology, infectious disease capabilities on 26 September. Read More
Charles River Laboratories International has opened a new Charles River Accelerator and Development Lab (CRADL) facility on Chestnut Street in Somerville, Massachusetts, an emerging life sciences hub. The facility is co-located with Nest.Bio, a provider of rentable BSL-2 laboratory and office space. The Chestnut Street… Read More
Charles River Laboratories has announced the launch of its Virtual Control Groups (VCG) initiative with Sanofi. The companies are working together to reduce animal usage by replacing selected control group animals with selected matched virtual control animals developed using retrospective datasets. The VCG collaboration… Read More
Charles River Laboratories International has launched its Alternative Methods Advancement Project (AMAP), an initiative focused on developing alternatives to reduce animal testing. The company has invested $200 million over the past four years to reduce the use of animal testing and has a five-year goal of… Read More
Charles River Laboratories has reported achieving 92% renewable energy usage worldwide in its 2023 Corporate Citizenship Report. The 2023 report evaluates the company’s progress across its strategic Environmental, Social and Governance (ESG) areas of focus: Accelerate Life-Saving Therapies; Lead with Integrity; Inspire our People; and Protect… Read More
The US Food and Drug Administration’s (FDA) Research to Accelerate Cures and Equity (RACE) for Children Act now requires all oncology drugs to be tested for paediatric indications ahead of approval. The EU regulation of the European Medicines Agency (EMA) is also being adapted to mirror… Read More
Charles River Laboratories has revealed plans to open Charles River Accelerator and Development Lab (CRADL) locations in Seattle and Philadelphia, expanding the company’s contract vivarium space for the biopharmaceutical industry. CRADL Seattle is opening this September as Charles River’s most recent investment in Seattle, providing flexible… Read More
This article is sponsored by Charles River. Research tools, safety testing and regenerative medicines – these endless stem cell applications are powering precision, speed, and new modalities in drug development. Stem cells for use in drug discovery Stem cells are fast becoming an invaluable tool in the drug… Read More
Charles River Laboratories and Pioneering Medicines have entered a multi-programme agreement that gives Pioneering Medicines access to artificial intelligence (AI) model Logica. Through the agreement, Pioneering Medicines will apply Logica across a portfolio of targets with the aim of creating optimised small molecules… Read More
